Abstract
BackgroundChina’s National Reimbursement Drug List (NRDL) has become the primary route for drug reimbursement in China. More recently, the authority has made pharmacoeconomic evaluation an integral part of the application...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have